Compare Ross Stores, Inc. (ROST) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ross Stores, Inc. vs Vertex Pharmaceuticals Incorporated — how do they compare? Ross Stores, Inc. trades at $233.99 (market cap $75.63B), while Vertex Pharmaceuticals Incorporated trades at $478.12 (market cap $121.95B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Ross Stores, Inc. pays a 0.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| ROST | VRTX | |
|---|---|---|
Market Cap | $75.63B | $121.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $240.13 | $529.59 |
52-Week Low | $134.02 | $366.54 |
Enterprise Value | $76.23B | $116.69B |
Dividend Yield | 0.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ross Stores (ROST) trades at $235.78, up 1.05% today, with a bullish technical outlook supported by moving averages and recent earnings beats. The company reported strong Q1 2026 results with 21% sales growth and expanding margins, while expanding its store footprint with 47 new locations in mid-2026. Valuation metrics show a P/E of 32.93 and robust profitability with a 38.98% ROE, though the stock trades near analyst price targets.
The outlook remains positive due to consistent earnings outperformance and store expansion, but risks include high valuation multiples and competitive retail pressures. Analyst consensus is bullish with a $259 price target, suggesting moderate upside potential from current levels amid broader market volatility.
Vertex Pharmaceuticals (VRTX) trades at $482.00, down 0.75% on the day, with mixed technical signals showing a bullish overall trend but bearish moving averages. The company maintains strong fundamentals with $12.0B revenue (2025), 35.51% net margin, and recent earnings beats. Vertex's $10B acquisition of Crinetics Pharmaceuticals adds significant growth potential in endocrinology treatments.
The outlook remains positive with 85.7% analyst buy ratings and $538 consensus target offering 11.6% upside. Key risks include integration challenges from the Crinetics acquisition and competitive pressures in biopharmaceutical markets. Strong cash flow generation and profitability support continued growth despite recent volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ross Stores, Inc.
Ross Stores is a leading American off-price apparel and home fashion retailer, operating over 1,920 stores (at the end of fiscal 2021) across the Ross Dress for Less and dd's Discounts banners. Ross offers a variety of name-brand products and targets undercutting conventional retailers' regular prices by 20%-70%. The company uses an opportunistic, flexible merchandising approach
Read more on ROST →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
